Definium's LSD Phase 3 breakthrough for depression

[Nelson Vergel]

Definium Therapeutics (DFTX) — DT120 Phase 3 Emerge: Key Points


The Company

• Formerly MindMed, rebranded to Definium Therapeutics in January 2026 (ticker: DFTX)
• Developing DT120 ODT — a pharmaceutically optimized, fast-dissolve tablet formulation of LSD (lysergide tartrate)
• Market cap now ~$5.5B after shares spiked 30%+ on the news

The Trial

• Phase 3 "Emerge" study — 149 adults with moderate-severe MDD across 20 sites
• Single 100 µg dose of DT120 vs. placebo; 12-week blinded phase + 40-week open-label extension
• First-ever Phase 3 readout for LSD as a medicine

The Results

• Primary endpoint (MADRS at Week 6): -8.1 point placebo-adjusted difference, p<0.0001
• Week 1 (rapid onset): -14.2 points — faster than the Week 6 primary
• Week 12 (durability): -7.3 points — still statistically significant
• Response rate: 35% vs. 7% placebo; Remission: 24% vs. 3% placebo
• Benchmarks favorably against Spravato, Trintellix, Auvelity, and Compass's psilocybin

Safety

• No serious adverse events; no suicidality signal
• 99% of side effects mild-to-moderate and resolved within the dosing day
• All participants cleared the End of Session Checklist by hour 8 (average: 5.8 hrs)

What Makes It Different

• Single supervised session, not daily medication and not psychotherapy
• Attendant provides "grounding" support only — not a therapeutic intervention
• CMO Karlin calls LSD "the best drug in the category" — potent but gentle

Regulatory Path

• FDA Breakthrough Therapy designation already in hand for GAD (not MDD yet)
• Approval likely to target treatment-resistant MDD first (2 prior antidepressant failures)
• Definium excluded from XXXXX's priority vouchers (Compass, Usona, Transcend received them)
• Karlin: "What we don't want is an approval that has a political flavor to it"

Upcoming Catalysts

• Voyage (Phase 3 GAD) — topline expected early Q3 2026
• Panorama (Phase 3 GAD with 50 µg control arm) — topline late Q3 2026
• Ascend (2nd pivotal MDD study with 50 µg arm to address unblinding concerns) — topline 2027
• Haven (Phase 3 PTSD) — initiating 2027

Financials

• $373M cash at March 31, 2026; runway into 2028
• Announced $700M capital raise following the readout
• Q1 2026 net loss: $77M; R&D spend running at $41.5M/quarter

Key Risks

• Replication: one positive study is not an approval package; Ascend is critical
• Functional unblinding: patients may infer treatment assignment from the psychedelic experience
• DEA scheduling: FDA approval and rescheduling are separate hurdles
• Commercial complexity: requires trained sites, monitoring protocols, controlled-substance logistics
• Reimbursement: payers must accept a "procedure-like" one-session cost model

 

[Nelson Vergel]

Thread 'The Psychedelic Medicine Pipeline 2026'

Jan 11, 2026

The psychedelic drug development landscape has reached an inflection point in early 2026, with Compass Pathways achieving the first positive Phase 3 psilocybin trial results in June 2025, while Lykos Therapeutics' MDMA rejection has reshaped industry expectations for regulatory rigor. Six compounds now hold FDA Breakthrough Therapy Designation, and a potential FDA policy shift toward single-trial approvals could accelerate the path to market. This report provides a comprehensive status update on all major Phase 2/3 programs as of January 2026.

1. Regulatory Landscape​

1.1 The...​

• Nelson Vergel
• ketamine depression psychedelic drugs psychedelic studies psychedelics; depression; anxiety; ptsd; addiction psylocibin
• Replies: 3
• Forum: Mental Health

•